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differentiation medium. Bars show mean and s.d. of three independent experiments. Expression levels were normalized on GAPDH and 18S and compared to
that of cells at T0 (cells harvested at the beginning of the differentiation protocol). Un, untreated cells. ns, non-significant; *P<0.05,
§P<0.001.
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High-throughput screening for modulators of ACVR1 transcription:
discovery of potential therapeutics for fibrodysplasia ossificans
progressiva
Serena Cappato1, Laura Tonachini1, Francesca Giacopelli1, Mario Tirone2,3, Luis J. V. Galietta4,
Martina Sormani3, Anna Giovenzana3, Antonello E. Spinelli5, Barbara Canciani6, Silvia Brunelli3,
Roberto Ravazzolo1,4 and Renata Bocciardi1,4,*
ABSTRACT
The ACVR1 gene encodes a type I receptor of bone morphogenetic
proteins (BMPs). Activating mutations in ACVR1 are responsible for
fibrodysplasia ossificans progressiva (FOP), a rare disease
characterized by congenital toe malformation and progressive
heterotopic endochondral ossification leading to severe and
cumulative disability. Until now, no therapy has been available to
prevent soft-tissue swelling (flare-ups) that trigger the ossification
process. With the aim of finding a new therapeutic strategy for FOP,
we developed a high-throughput screening (HTS) assay to identify
inhibitors of ACVR1 gene expression among drugs already
approved for the therapy of other diseases. The screening, based
on an ACVR1 promoter assay, was followed by an in vitro and in
vivo test to validate and characterize candidate molecules. Among
compounds that modulate the ACVR1 promoter activity, we
selected the one showing the highest inhibitory effect,
dipyridamole, a drug that is currently used as a platelet anti-
aggregant. The inhibitory effect was detectable on ACVR1 gene
expression, on the whole Smad-dependent BMP signaling pathway,
and on chondrogenic and osteogenic differentiation processes by in
vitro cellular assays. Moreover, dipyridamole reduced the process
of heterotopic bone formation in vivo. Our drug repositioning
strategy has led to the identification of dipyridamole as a possible
therapeutic tool for the treatment of FOP. Furthermore, our study
has also defined a pipeline of assays that will be useful for the
evaluation of other pharmacological inhibitors of heterotopic
ossification.
KEY WORDS: ACVR1, Transcriptional regulation, BMP signaling
pathway, FOP, Dipyridamole, High-throughput screening, Drug
repositioning
INTRODUCTION
Fibrodysplasia ossificans progressiva (FOP; OMIM 135100) is a
rare genetic disease with a prevalence of about one per 2-million
people. The inheritance is autosomal dominant, althoughmost cases
are due to sporadic new mutations (Shore et al., 2005). Individuals
with FOP are characterized by a peculiar congenital toe
malformation and, usually starting within the first decade of life,
by a progressive heterotopic ossification (HO) that takes place
following some types of injury (such as trauma, medical surgery,
intramuscular immunization, infections) or spontaneously.
Inflammatory soft-tissue swellings, commonly called flare-ups,
progressively transform skeletal muscles, tendons, ligaments, fascia
and aponeuroses into a second skeleton of heterotopic bone (Kaplan
et al., 2008).
The FOP gene (ACVR1) encodes a type I receptor of bone
morphogenetic proteins (BMPs), ACVR1 (also known as ALK-2).
The most recurrent ACVR1 mutation is in the glycine-serine (GS)
domain (c.617G>A, p.R206H) (Shore et al., 2006). Additional
mutations have been identified in the GS and in the kinase domain
of the protein in 3% of all known individuals with FOP (for a
review, see Kaplan et al., 2009; Bocciardi et al., 2009). The
consequence of ACVR1 mutations is an alteration of inter-
intramolecular interaction of the mutant receptor that causes a
deregulation of the downstream BMP signaling (Shore et al., 2006;
Bocciardi et al., 2009; van Dinther et al., 2010; Song et al., 2010;
Groppe et al., 2011; Chaikuad et al., 2012).
At present, no established medical treatment is available for FOP.
Early diagnosis prevents unnecessary interventions, such as
biopsies or surgical operations that can exacerbate the progression
of the disease, and high-dose glucocorticoids are used in the
management of inflammatory flare-ups (Kaplan et al., 2013).
In recent years, much effort has been devoted to designing new
therapeutic approaches to FOP treatment and to identify new,
potentially useful, drugs (Kaplan et al., 2013; Sanvitale et al., 2013;
Yu et al., 2008a; Kitoh et al., 2013). A promising alternative to the
discovery of new drugs is the drug repositioning strategy, in which a
drug already developed for a specific disease can be used to treat a
different condition. Drug repositioning reduces costs and accelerates
the drug development process. Moreover, this approach might
contribute to clarify the mechanism of action of a given compound
by establishing a relationship between the molecular basis of the
disease and the ability of the compound to intervene at a certain step
of the disease process (Shameer et al., 2015).
A possible strategy to find drugs for the treatment of a genetic
disease could rely on a sensitive, specific and fast cell-based assay.
In this way, a large number of small molecules can be screened
[high-throughput screening (HTS)] to find agents that correct theReceived 12 November 2015; Accepted 22 April 2016
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basic defect. The recent identification and characterization of the
promoter region of ACVR1 (Giacopelli et al., 2013) inspired us to
develop an HTS assay by generating cells stably expressing the
luciferase reporter gene controlled by a 2.9-kb region of the gene
promoter. We expected that this type of assay would allow the
identification of molecules that, by inhibiting the ACVR1 promoter,
would also negatively regulate the downstream signaling that is
upregulated and hyper-responsive to BMPs because of the mutation
in the receptor.
In this work, we describe the screening of a library of 1280 US
Food and Drug Administration (FDA)-approved compounds, in
order to identify modulators of ACVR1 gene expression.
Characterization of hit molecules included a series of second-level
assays to evaluate the effect of compounds on chondrogenic and
osteogenic differentiation models in vitro and in vivo.
We found that dipyridamole, commonly used as an
antithrombotic and vasodilator drug, has an inhibitory effect on
ACVR1 expression, as well as on the whole BMP signaling pathway,
and is able to affect chondrogenesis and osteogenesis, both in
cellular assays and in a BMP-induced HO mouse model.
RESULTS
Screening of the Prestwick Chemical Library
Our primary screening was designed to find drugs that downregulate
BMP signaling by targeting the expression of the ACVR1 gene at the
transcriptional level. Accordingly, we developed a quantitative
assay based on expression of a reporter gene under the control of
the ACVR1 promoter. To this end, we generated clones of the
ATDC5 cell line (mouse chondrogenic cell line derived from
teratocarcinoma) stably expressing the luciferase coding sequence
under the control of the 2.9-kb promoter of the gene, previously
characterized by our group (Giacopelli et al., 2013). We obtained
several clones that were expanded and selected for the level and
stability of reporter gene expression over time. The availability of
different clones, with putative different integration sites of the
reporter construct in the genome of ATDC5 cells, allowed us to
verify that the effect measured for a given compound was not related
to a ‘position effect’ operated by the genomic region surrounding
the reporter construct itself.
The generated cell system and the compound analysis procedure
were tested by screening a small library of 43 molecules with
chromatin-modifier properties. This allowed us to validate the
protocol for the primary screening and provided us with a positive
control because we identified resveratrol as a transcriptional
activator of ACVR1 gene expression (Fig. S1).
We used these cells to screen the Prestwick Chemical Library,
which includes 1280 FDA-approved compounds, with the idea that
‘repositioning’ of an already approved drug could have the great
advantage to overcome several steps of the drug discovery process.
The screening detailed in Table 1 (see also Fig. S2) was performed
in duplicate: compounds were added to cells seeded in 96-well
plates for 24 h at the concentrations of 20 and 2 µM, respectively.
We included in each plate DMSO, the vehicle in which compounds
are dissolved, and resveratrol (20 µM) as a transcriptional activator
of the ACVR1 promoter and positive control. When we started this
work, no transcriptional inhibitors of the ACVR1 expression were
known. However, during the screening of the second plate of the
Prestwick Chemical Library, we detected dipyridamole as an
inhibitor of ACVR1 expression. Therefore, this compound was
subsequently included in all the remaining plates as an additional
control. To monitor the performance of the screening, we used the
Z′-factor statistical parameter (Zhang et al., 1999). The calculated
Z′-factor was 0.63±0.1 and 0.65±0.1 when considering resveratrol
and dipyridamole, respectively. These values are considered
optimal for an HTS assay (Zhang et al., 1999). During the
primary screening, we also evaluated the toxicity of all tested
compounds by an in situ fluorescence-based assay (Table 1 and see
Materials and Methods for details). We therefore normalized the
activity of the luciferase reporter gene driven by the ACVR1
promoter with a fluorescence signal proportional to the number of
viable cells at the end of the treatment. This allowed us to select
molecules not affecting cell viability, inducing a reduction in the
luciferase activity of at least 0.4- or an upregulation of at least 2.4-
fold compared to cells treated with DMSO (Table S1).
Validation assays of dipyridamole
According to our inclusion criteria, the primary screening provided
a list of compounds putatively working as activators (4 hits) or
inhibitors (18 hits) of ACVR1 transcriptional activity (listed in
Table S1). Among these latter molecules, we found that
dipyridamole (abbreviated henceforth as Dipy), was the
compound that, during the retesting of primary hits, generated the
Table 1. HTS assay protocol
Step Parameter Description
1 Cell plating (Pr2.9-
Luc ATDC5)
3×105 cells/well
2 Controls 10 μM resveratrol, positive control; 1%




1200 compounds diluted to 20 and
2 μM
4 Incubation 24 h at 37°C and 5% CO2
5 Viability assay Addition of 20 μl CellTiter-Fluor
reagent to living cells
6 Viability assay
(incubation)
1 h at 37°C and 5% CO2
7 Viability assay
(detection)
Detection of the fluorescent signal




Addition of the ONE-Glo reagent
(100 μl), cell lysis
9 Assay readout Detection of the luminescence signal
(GLOMAX Automated Plate Reader)
10 Evaluation of HTS
performance
Calculation of the Z’-factor statistical
parameter according to Zhang et al.
(1999)
11 Data analysis Evaluation of cell viability (Vi) and
effect of compounds (E) on the




1 96-well format culture plates
2,3 80 compounds per plate (columns 2 to 11); columns 1 and 12 were
used for positive, negative and neutral controls (8 wells for
DMSO, 4 wells for each control)
5-7 12-tip dispense of the CellTiter-Fluor reagent; automated
fluorescence detection
8-9 These steps are fully automated; the ONE-Glo reagent is added
in situ by injection followed by luminescence detection
10 0≥Z′≤1, with Z′≥0.5 for a good HTS (Zhang et al., 1999)
Z′(+Resv)=0.63±0.1 and Z′(−Dipy)=0.65±0.1
11 Evaluation of cell viability, Vi=(fluoCx/average fluoDMSO)×100
Normalization, Nx=LumCx/fluoCx and NDMSO=LumCx/fluoCx
Effect of compounds, E=(Nx/averageNDMSO)×100
*Identified in the second experimental plate and introduced as negative control
from plate 5 to 15.
686


















most reproducible and significant results. Therefore, Dipy was
selected for further experimental confirmations.
Dipy showed a dose-dependent suppression of the luciferase
activity driven by the ACVR1 promoter, with the strongest effect
at 50 µM (Fig. 1A). The inhibition was detectable after 6 h of
treatment for the highest dose, further increasing at 24 h (Fig. 1B).
Normalization of the luciferase activity and monitoring of cell
viability were obtained as described for the primary screening.
In accordance with the inhibitory effect of Dipy on the promoter
of the ACVR1 gene, we found that Dipy was able to downregulate
the expression of ACVR1 mRNA, as assessed by reverse-
transcription quantitative PCR (RT-qPCR), both in native ATDC5
and C2C12 (mouse myoblast cell line) cells (Fig. 1C). After 24 h of
treatment, we observed a gene-expression reduction of nearly 20%
at 20 µM and 60% at 50 µM.
The effect of Dipy on the expression of genes encoding other
type I and II receptors of the BMP family was also tested (Fig. S3).
The highest degree of mRNA reduction was exerted on ACVR1
(Alk2) but was also observed with Alk3 and BMPRII. Alk5,
involved in the growth differentiation factor (GDF)–transforming
growth factor β (TGF-β) signaling cascade, and Alk4, ActRIIa and
ActRIIb showed a low level of expression that was not affected by
Dipy. Other type I receptors, such as Alk1, Alk6 and Alk7, were not
expressed in ATDC5 cells.
Effect of dipyridamole on the Smad-dependent BMP pathway
In order to test the effect of Dipy on the activation state of the Smad-
dependent BMP signaling pathway, we generated ATDC5 clones
stably expressing the luciferase reporter gene under the control of a
minimal promoter carrying a BMP-responsive element (BRE-Luc)
isolated from Id1, a well-known BMP target gene (Monteiro et al.,
2008). Cells were treated with Dipy in the presence of BMP2 for
6 h. As reported in Fig. 2A, Dipy weakened the amplitude of the
activation induced by BMP2 in a dose-dependent manner.
Consistently, we found a downregulation in the mRNA
expression of native Id1, Id2 and Id3 target genes, as assessed by
RT-qPCR in ATDC5 cells (Fig. 2B), and a significant reduction in
the phosphorylation state of the Smad1/5 proteins both in ATDC5
and C2C12 cells (Fig. 2C,D and Table S2 for immunoblot
densitometric analysis).
Effect of dipyridamole on chondrogenic differentiation
The heterotopic bone that forms in individuals with FOP derives
from an endochondral ossification process. ATDC5 cells are able to
differentiate into mature chondrocytes when grown in three-
dimensional (3D) cultures in differentiating medium (Tare et al.,
2005).
ATDC5 cells were induced to develop 3D pellets in the presence
of differentiating medium (DM), with and without Dipy (50 µM).
After 3 weeks of culture, pellets were embedded in paraffin, and
histological sections stained with Alcian Blue to verify the
deposition of glycosaminoglycans typical of the cartilage
extracellular matrix. As shown in Fig. 3A (left panels), compared
to what was observed in proliferative medium (PM), pellets grown
in DM are characterized by the presence of cells with peculiar
morphology, with typical lacunae embedded in the extracellular
matrix. By contrast, pellets grown in the presence of Dipy, both in
PM and DM, showed the presence of small and undifferentiated
cells (Fig. 3A, right panels).
The result was confirmed in ATDC5 cells cultured in alginate
spheres. In the presence of inductive medium, we observed changes
in cell morphology correlating with the differentiation state
(Fig. 3B, upper panels). By contrast, treatment with Dipy induced
a significant reduction of extracellular-matrix deposition as assessed
by Alcian Blue staining of sections (Fig. 3B, left panels) and
reduced expression of matrix proteins Sox9 and collagen II (Col II)
as assessed by immunohistochemical analysis with specific
antibodies (Fig. 3B, central and right panels, respectively).
Fig. 1. Cellular assays of Dipy treatment. (A) Dose-response curve of Dipy
on the luciferase reporter gene controlled by the promoter region of ACVR1 in
ATDC5 cells (Pr2.9-Luc). The ratio of luciferase (Luc)/fluorescence (Fluo) was
normalized to that obtained with DMSO [untreated (Un); value 100]. Bar graph
represents the mean and s.d. of three independent experiments. §P<0.001.
(B) Time course of Dipy treatment in ATDC5 Pr2.9-Luc clones. The ratio of
luciferase/fluorescencewas normalized to that obtained with DMSO (Un; value
100) for each time point. (C) Effect of Dipy on the expression of ACVR1mRNA
in native ATDC5 and C2C12 cells. Values were normalized on GAPDH and
β2M and compared to expression level measured in cells treated with DMSO
(Un). Bar graphs represent the mean and s.d. of at least three experiments,
*P<0.01, §P<0.001, ns, non-significant.
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In accordance, RT-qPCR analysis on mRNA extracted from cells
cultured in alginate spheres showed that the expression level of
ACVR1 and markers of cartilage differentiation [Runx2, Sox9,Col II
and collagen X (Col X)] was downregulated upon Dipy treatment
compared to untreated cells (Fig. 4).
Effect of dipyridamole on osteogenic differentiation
We also investigated the effect of Dipy on the osteoblastic
transformation of C2C12 cells upon BMP2 induction (Katagiri
et al., 1994). As shown in Fig. 5A and B, Dipy caused a dose-
dependent reduction in alkaline phosphatase activity without
significantly affecting cell viability (Fig. S4). The effect was
accompanied by a downregulation of the mRNA of markers
typical of the osteoblastic differentiation – Runx2, osterix and
osteocalcin – which was statistically significant at the highest dose
(Fig. 5C). During the differentiation process, in the presence of
Dipy, we confirmed the reduction in the expression of ACVR1
mRNA.
Effect of dipyridamole on heterotopic ossification in a BMP-
induced mouse model
We examined the effect of Dipy on a BMP-induced model of HO
in vivo. C57BL/6 2-month-old mice were injected with BMP2
intramuscularly in the quadriceps and treated with vehicle or 10 mg/
kg (body weight) Dipy, administered daily by intra-peritoneal (IP)
injection as described in Wang et al. (2013), according to two
different experimental protocols as schematically represented in
Fig. S5. Serum concentration of Dipy in mice was assessed
according to Oshrine et al. (2005), and results were comparable to
what was described in the same work (not shown).
Ossicle formation and HO volume were evaluated by μCT scan
after 10 (n=6 for each group, Fig. S5 protocol A) and 21 (n=11 for
each group, Fig. S5 protocol A) days of treatment. After 10 days of
treatment, we observed highly variable volumes of HO (mineralized
volume, mm3) in control mice and no significant difference in HO
volume was observed in treated mice compared to controls
(Fig. 6A,B). By contrast, after 21 days of treatment, μCT scans
showed a significant reduction of HO volume in mice treated with
Dipy compared to controls (Fig. 6C,D). Histological analysis
revealed that HO lesions (Fig. 7A) in treated mice were reduced,
possibly due to a delay in maturation. In particular, Toluidine Blue
staining indicated a reduced deposition of cartilage matrix, also at
10 days of treatment (Fig. S6), whereas Alizarin Red staining at
21 days and quantification of the area of calcium deposition showed
a decrease in lesions of Dipy-treated mice (Fig. 7B,C), in agreement
with the μCT scan results.
Smad1/5 phosphorylation in the injured tissue was assessed at the
two different time points, 10 and 21 days, by immunofluorescence
with a specific anti-phospho-Smad1/5 (p-Smad1/5) antibody.
We observed that, at 10 days after injury, the number of cells
showing Smad phosphorylation was higher than at 21 days. This
is consistent with the ongoing osteogenic differentiation of the
HO lesions at the early time point, when the extent of mature
heterotopic ossification was still comparable in untreated and
treated mice, as described above. This is also indicated by the
shape and intensity of p-Smad staining per cell. Interestingly, the
effect of Dipy at this stage was already detectable as a
statistically significant reduction in the expression of p-Smad1/5
(Fig. S7). This decrease was still present as a trend at 21 days of
treatment (Fig. S7B), when the overall number of p-Smad1/5-
positive cells was reduced in the lesions of both control and
treated mice.
When Dipy was administered to the mice starting from 10 days
after the ossification trigger by BMP2 (Fig. S5, protocol B), the
μCT-scan analysis of ectopic lesions (Fig. S8A) showed a trend of
reduction (P=0.074) of the HO volume increase between 10 and
21 days (Fig. S8B,C). Histological analysis revealed that, at day 21,
calcium deposition was also significantly reduced as assessed by
Alizarin Red staining (Fig. S9A) and corresponding quantification
(Fig. S9B).
Fig. 2. Effect of Dipy on the BMP-mediated
signaling pathway. (A) Luciferase activity measured
in ATDC5 BRE-Luc cells treated with the indicated
doses of Dipy and activated with [50 ng/ml] BMP2.
The ratio of luciferase (Luc)/fluorescence (Fluo) was
normalized to that obtained with DMSO (value 100).
Bar graph represents the mean and s.d. of three
independent experiments. §P<0.001. (B) Effect of
Dipy on the expression level of Id1, Id2 and Id3 BMP
target genes in native ATDC5 cells. Values were
normalized on the β2M reference gene (relative
quantification by the ΔCt method: ratio reference/
target=2ΔCt). Bars represent the mean and s.d. of
three independent experiments. ns, non-significant;
*P<0.05, #P<0.01, §P<0.001. (C,D) Effect of Dipy on
the activation of the Smad-dependent pathway.
ATDC5 (C) and C2C12 (D) cells were treated with
Dipy and activated with [200 ng/ml] BMP2 for 1 h.
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To date, no therapy is available to prevent or control HO in FOP
patients. Therefore, intense work is being carried out to find
potential therapeutic intervention essentially based on inhibition of
BMP signaling using different approaches (Kaplan et al., 2013).
The rationale basis of a therapeutic approach for FOP is that small
molecules might function as inhibitors, thus correcting the hyper-
functioning BMP signaling pathway(s), either by inhibiting directly
the receptor function or the transcriptional or post-transcriptional
expression of the encoding gene, which will in turn result in the
quantitative reduction of the receptor protein.
Following the identification of dorsomorphin as an inhibitor of
BMP type I receptors, through HTS in zebrafish (Yu et al., 2008b),
other inhibitors have been described (Yu et al., 2008a; Cuny et al.,
2008; Hao et al., 2010). Previously published work demonstrated
that treatment of bone-marrow-derived mesenchymal stem cells
(MSCs) with RAR-γ agonists negatively regulates BMP signaling.
This is due to the reduction of the intracellular concentration of
p-Smads by a post-translational mechanism of degradation,
supporting the idea that quantitative reduction of components of
this pathway might cause a reduction of signaling function
(Sanvitale et al., 2013; Shimono et al., 2011; Sheng et al., 2010).
In the current work, we introduced an HTS approach aimed at
identifying potential therapeutic candidates acting by modulation of
the ACVR1 gene expression. The primary screening was made
possible by the generation of a cell system consisting of murine
ATDC5 cells stably expressing the luciferase gene controlled by the
2.9-kb promoter region of ACVR1 that was previously identified and
functionally characterized by our group (Giacopelli et al., 2013).
Our method was able to pinpoint molecules with both positive and
negative effects. However, in the context of FOP pathogenesis, in
which activating mutations of ACVR1 cause an inappropriate BMP-
mediated signaling, our interest was focused on molecules able to
reduce the expression level of the gene.
In addition to the primary screening, our approach included
assays to confirm the effect of candidate molecules on the different
steps of the BMP pathway, on chondrogenic and osteogenic
differentiation processes and on HO in vivo. The experimental
procedure described in this workflow can also be exploited to test
compounds able to affect BMP signaling, even when discovered by
other cell-based HTS assays or by in silico virtual screening
approaches.
An advantageous approach to search for innovative treatments for
rare disease in a relative short time is to perform an HTS approach
with a drug repositioning purpose (Muthyala, 2011; Li and Jones,
2012; Sardana et al., 2011; Yamamoto et al., 2013). To this aim,
we screened a library of 1280 FDA-approved compounds. We
identified a list of interesting molecules with positive or negative
effect and decided to focus on the candidate with the most
significant effect as a transcriptional inhibitor, dipyridamole.
Validation assays confirmed a specific negative effect of Dipy on
the ACVR1 gene expression and demonstrated that such an effect
resulted in the attenuation of the entire BMP-specific signaling
pathway. This was demonstrated by the reduction of BMP2-induced
activation tested by the luciferase reporter gene under the control of
BMP-responsive element (BRE-Luc). Consistently, this effect was
Fig. 3. Histological analysis of ATDC5
chondrogenic differentiation. (A) Alcian Blue
staining of sections from ATDC5 cell 3D cultures
grown in proliferative medium (PM, upper panels)
and in differentiation medium (DM, lower panels), in
the presence of 50 µM Dipy or DMSO. Scale bars:
100 μm (10×) and 50 μm (20×). (B) Histological and
immunohistochemical analysis of ATDC5 cells
cultured as alginate spheres grown in DM in the
presence of DMSO or 50 µM Dipy (upper and lower
panels, respectively). Scale bars: 25 μm.
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confirmed as reduced expression of the Smad-signaling target genes
Id1, Id2 and Id3, and as reduced phosphorylation of Smad1/5
mediators.
Although the highest effect of Dipy treatment was found to
impact ACVR1 (Alk2) expression, we found that Dipy could also
affect the expression of other BMP receptors that can synergistically
contribute to the downregulation of the overall BMP signaling, such
as, among type I receptors, Alk3 or, among type II, BMPRII, which
cooperates with ACVR1 as a type I partner in the receptor complex.
It is of interest to note that Dipy did not affect the expression of
specific receptors, such as Alk5, which is involved in cascade
mediated by TGF-β type I, or Alk4, ActRIIa and ActIIb, which
intervene in GDF-BMP signaling. This finding suggests that the
downregulating effect of Dipy is mainly, but not exclusively,
exerted on Alk2 (ACVR1), possibly because of common regulatory
mechanisms for the expression of molecules belonging to the same
family and participating in common pathways.
Because HO in FOP derives from an endochondral ossification
process (Kaplan et al., 1993; Medici and Olsen, 2012; Shore, 2012),
we set up assays to evaluate both chondrogenesis and osteogenesis.
To simulate differentiation in vitro, we took advantage of the ability
of ATDC5 cells to differentiate towards mature chondrocytes in 3D
cultures, with cell morphological changes and deposition of
glycosaminoglycans typical of the cartilage extracellular matrix.
Using this assay, we observed that Dipy could inhibit chondrogenic
differentiation.
Fig. 4. Effect of Dipy on the expression of chondrogenic
markers. RT-qPCR on RNA extracted from ATDC5 cells
cultured as alginate spheres for 14 days in differentiation
medium. Bars show mean and s.d. of three independent
experiments. Expression levels were normalized on GAPDH
and 18S and compared to that of cells at T0 (cells harvested at
the beginning of the differentiation protocol). Un, untreated
cells. ns, non-significant; *P<0.05, §P<0.001.
Fig. 5. Effect of Dipy on osteoblastic
differentiation of C2C12 cells. (A) Specific
staining for alkaline phosphatase activity in
C2C12 native cells cultured for 6 days in the
presence of [200 ng/ml] BMP2, ±Dipy as
indicated (20 or 50 μM). Un, untreated.
(B) ALP activity measured in C2C12 cells
treated as in A, normalized against the
number of nuclei (cells) obtained by
automated count after Hoechst staining in
each well (see Materials and Methods and
Fig. S3). (C) Gene expression level of
osteogenic marker genes in C2C12 untreated
or treated with Dipy (20 or 50 μM). Bar graphs
represent mean and s.d. of three independent
experiments. mRNA levels were normalized
on GAPDH and 18S and compared to that
measured in untreated cells (value 1). NFE,
normalized fold expression; ns, non-
significant; *P<0.05, #P<0.01, §P<0.001.
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C2C12 cells were used to evaluate osteogenic differentiation,
which was inhibited by Dipy as indicated by the reduction in the
alkaline phosphatase (ALP) activity and expression of different
markers (Runx2, osterix and osteocalcin).
The effect of Dipy was also verified in vivo in a BMP-induced
mouse model of HO (Medici et al., 2010). During the induction of
the ectopic ossification process, triggered by the implantation of a
BMP2-embedded Matrigel coupled to cardiotoxin (CTX) injection,
muscle fibers degenerate and the site of injury is infiltrated by
different populations of inflammatory cells that contribute to the
orchestration of the subsequent repair/differentiation process
(Zordan et al., 2014; Rigamonti et al., 2014). During the first
week after injury, progenitor cells of different origin are then
recruited to the site of the lesion (Bentzinger et al., 2013) and
committed towards the endochondral ossification process by the
local presence of BMP2. At 10 days, HO lesions are not completely
differentiated, and recruitment and activation of cells is ongoing:
this was consistent with our finding that, at this stage, the overall
number of cells able to respond by activating a specific BMP2/
Smad-dependent signaling was higher than what was observed at
21 days after BMP2 induction.
At the earliest time point, the effect of treatment with Dipy
became evident as a statistically significant decrease in the number
of cells expressing an activated BMP/Smad pathway inside the
HO lesions that finally resulted in the reduction of the volume
of mineralized heterotopic ossicles, of decreased deposition of
extracellular matrix and of a reduced area of calcified nodules that
we observed after 21 days of treatment.
Most interestingly, Dipy effect was evident also when mice were
treated after the establishment of heterotopic ossification, and
resulted in a reduced calcium deposition within the ectopic bone and
a decreased mineralization. However, concerning the choice of an
in vivo prevention strategy versus a treatment on established/
ongoing lesions, it is important to consider that the course of FOP is
episodic with quiescent phases, lasting even for years, and acute
phases that can be triggered by several types of recognizable stimuli
(trauma, vaccinations, infection, iatrogenic harms etc.), but that can
also occur apparently spontaneously or, more likely, without a
recognizable trigger. In this context, a treatment for FOP is ideally a
drug that can be administered chronically or for long periods of time
in order to prevent the occurrence of even unpredictable flare-ups,
thus counteracting their consequences.
Dipy is a commercially available drug that was introduced on the
market more than 50 years ago as a coronary vasodilator (Kadatz,
1959). At present, it is widely used as an antithrombotic and
vasodilator agent both as monotherapy and in combination with
aspirin to prevent secondary stroke or transient ischemic attack
(Gresele et al., 2011; Balakumar et al., 2014; de Vos-Koppelaar
et al., 2014). At the pharmacological level, Dipy acts by different
mechanisms. By inhibiting the activity of phosphodiesterases 5 and
3 (PDE5 and PDE3), it increases the intracellular level of cyclic
adenosine monophosphate (cAMP), which is a potent inhibitor of
platelet activation, and of cyclic guanine monophosphate (cGMP),
which has a vasodilator effect on smooth muscle, thus potentiating
the platelet inhibitory actions of prostacyclin (PGI2) (Gresele et al.,
2011; de Vos-Koppelaar et al., 2014; Kim and Liao, 2008; Yip and
Benavente, 2011). Moreover, Dipy inhibits the re-uptake of
adenosine by blocking the equilibrative nucleoside transporters
(ENTs), thus increasing plasma levels of this nucleoside, which also
plays a role in inhibiting platelet aggregation (Kim and Liao, 2008;
Visser et al., 2005; Dresse et al., 1982; German et al., 1989),
regulation of vascular tone, vasodilation, immunity and
inflammation (Kim and Liao, 2008).
It should be noted that the effect of Dipy in our in vitro assay of
C2C12 cells was not in accordance with other in vitro experiments
performed to correlate adenosine level to osteoblast differentiation
(Costa et al., 2011; He et al., 2013). This discrepancy might be due
to differences in the cellular model and experimental conditions.
Moreover, very recently, Mediero and colleagues (2015) reported
that local daily injection of Dipy administered with a collagen
sponge was able to induce bone regeneration and proposed this
treatment as an alternative to recombinant human BMP2 (rhBMP2).
At difference with the above report, in the BMP-induced in vivo
model that we used, HO was locally triggered in quadriceps
muscles, whereas treatment with Dipy was systemic, by daily IP
injection. Moreover, it has been shown that, in humans, blood cells
tend to accumulate the drug (Serebruany et al., 2009), and Dipy is
able to inhibit at the mRNA level the production of TNF-α and
Fig. 6. Effect of Dipy on HO in vivo.
(A) Micro-computerized tomography (μCT)
scans of C57BL/6 mice treated with
vehicle or Dipy (10 mg/kg body weight) for
10 days. (B) Quantification of the
mineralized ossicle volume. n=6 mice/
condition. (C) μCT scans of C57BL/6 mice
after 21 days of treatment with vehicle or
Dipy (10 mg/kg body weight).
(D) Quantification of the mineralized
ossicle volume (left panel) and lesion bone
density (HU/mm3, right panel). n=11 mice/
condition. Bars represent mean and s.e.m.
#P<0.01. HU, Hounsfield unit.
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MMP-9 of peripheral blood mononuclear cells (PBMCs) and
derived macrophages (Massaro et al., 2013). Because several types
of immune cells are recruited at the site of HO lesions, this might
contribute to the overall effect observed in our HO model.
Several observations suggest a role of an immune-mediated
response in FOP pathogenesis, in particular a possible relevant
contribution to the episodic neo-formation of ectopic bone. In
humans, FOP flare-ups can be triggered or exacerbated by trauma,
immunizations, medical procedures and infections, all of which are
conditions in which the immune response is solicited/stimulated
(for a review, see Kaplan et al., 2016). Both in humans and in animal
models, histological examination of early pre-osseous lesions has
clearly demonstrated that several types of immune cells, such as
lymphocytes, monocytes/macrophages and mast cells, are readily
recruited to these sites (Kaplan et al., 1993; Chakkalakal et al.,
2012). In addition, it has been demonstrated that in vivo targeted
ablation of macrophages or of macrophages and mast cells
concomitantly leads to a significant reduction in the ectopic bone
formation in FOP mouse models (Kan et al., 2009; Convente et al.,
2015).
The deregulated BMP signaling in cells harboring the mutated
ACVR1 gene might contribute to the amplification of inflammatory
pathways (Convente et al., 2015); moreover, it has been recently
demonstrated that the presence of FOP mutations specifically
confers to the mutated receptor the ability to respond to activin A
(Hatsell et al., 2015; Hino et al., 2015). Activin A is a ligand
member of the TGF-β superfamily that is rapidly released during
inflammation and considered a crucial mediator of inflammation
and immunity. Its activity is stimulated by inflammatory cytokines,
Toll-like receptor ligands and oxidative stress, and it is involved
in regulating growth and maturation of mast cells, monocyte/
macrophage differentiation, and interaction between natural killer
(NK) and dendritic cells (Funaba et al., 2003; Ogawa and Funaba,
2011; Aleman-Muench and Soldevila, 2012; Seeger et al., 2014).
Given the known pleiotropic effect of Dipy, with anti-
inflammatory, anti-oxidant and anti-proliferative properties, and
Fig. 7. Chronic Dipy treatment decreases BMP2-
induced HO lesions and calcium deposition.
(A) Hematoxylin and eosin (H&E) staining showing
lesions in muscle injected with BMP-2 and cardiotoxin in
mice treated with vector or Dipy for 10 or 21 days. No
lesions appear in muscle damaged without BMP. Scale
bars: 1 mm. (B) Alizarin Red S staining showing calcium
deposition in tissue sections of muscle injected with
BMP2 and cardiotoxin in mice treated with the vehicle or
Dipy for 21 days. Scale bars: 500 μm. (C) Graph
representing the relative quantification of the Alizarin-Red-
S-positive area. Data represent mean±s.e.m. *P≤0.05
(n=3, Dipy versus control).
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the complexity of the action of a drug in vivo, related to its
absorption, metabolism and distribution, we cannot exclude that the
observed decrease of ectopic ossification in our in vivomodel might
depend on the involvement of different pathways. However, we
showed that Dipy is also able to affect specifically the Smad-
dependent pathway in HO lesions of treated mice.
Summarizing, the overall effect of Dipy on the process of HO
in vivo might be mediated by different mechanisms of action, such
as the metabolic effect of extracellular adenosine, regulatory
properties on differentiation and activation of immune cells, and
anti-inflammatory action.
In conclusion, our study implicates this molecule as a candidate
drug for the treatment of FOP, considering the great advantage that
Dipy is already widely used in the therapy of cardiovascular
disorders, and that safety and adverse effect profiles have already
been evaluated and established.
MATERIALS AND METHODS
Chemicals and reagents
The Prestwick Chemical Library was purchased from Prestwick Chemical
(Illkirch-Graffenstaden, France) and supplied in a special academic format
with the 1280 FDA-approved compounds at 10 mM concentration in
DMSO, in 16 96-well format plates, each containing 80 compounds.
Resveratrol (CAS no. 501-36-0, Enzo Life Sciences, Farmingdale, NY,
USA) and dipyridamole (CAS no. 58-32-2, Sigma, Buchs, SG, Switzerland)
were dissolved in DMSO and prepared as 1 M and 200 mM stock solutions,
respectively.
Recombinant human BMP2 [rhBMP2; Chinese hamster ovary (CHO)-
derived, R&D Systems, Minneapolis, MN, USA] was prepared as a 100 µg/
ml stock solution in 4 mM HCl containing 0.1% bovine serum albumin
(BSA; Sigma-Aldrich, Buchs, SG, Switzerland).
Antibodies for western blot analyses were: anti-p-Smad1/5 (13820S, Cell
Signaling, Danvers, MA, USA), anti-GAPDH (MAB3749, Millipore,
Billerica, MA, USA), and horseradish peroxidase (HRP)-conjugated anti-
rabbit and anti-mouse secondary antibodies (Dako, Glostrup, Denmark). For
immunohistochemical analyses, the following antibodies were used: rabbit
anti-bovine polyclonal antibody anti-collagen type II (AB746P, Millipore,
Billerica, MA, USA), rabbit polyclonal antibody anti-Sox9 (AB5535,
Millipore, Billerica, MA, USA), and anti-rabbit (K4002) and anti-mouse
(K4000) EnVision System-HRP Labelled Polymer (Dako, Glostrup,
Denmark).
Expression plasmid preparation
The isolation of the genomic region, corresponding to the ACVR1 promoter,
was previously described by our group (Giacopelli et al., 2013). The whole
2.9-kb genomic fragment was subcloned in the pGL4.17 vector (Promega
Corporation, Madison, WI, USA) upstream of the luciferase coding sequence
as a reporter gene; this expression plasmid carries the Neomycin-resistance
gene for selection of stable transfectants. The obtained reporter construct is
reported as Pr2.9-Luc throughout the present work. A second reporter gene
construct was also prepared by isolating a minimal promoter containing the
BMP-responsive element (BRE) of the Id1 gene from the pGL3-(BRE)2Luc
plasmid (kindly provided by Dr Peter ten Djike, Leiden University Medical
Center, Leiden, TheNetherlands) (Monteiro et al., 2008).BREwas transferred
in to the pGL4.17 vector upstreamof the luciferase reporter gene (referred to as
BRE-Luc) plasmid, carrying the Neomycin-resistance gene that allowed the
generation of stable transfectants as described below.
Cell culture
ATDC5 cells (mouse chondrogenic cell line derived from teratocarcinoma)
were obtained from the Cell Bank of the Riken BioResource Center upon
material transfer agreement (MTA); C2C12 myoblasts were purchased from
the ATCC Cell Biology Collection (LGC standards, Bury, Lancashire, UK).
ATDC5 cells were routinely cultured in complete medium consisting of 1:1
mixture of Dulbecco’s modified Eagle’s medium and Ham’s F-12 medium
(DMEM/F12), containing 5% fetal bovine serum (FBS,Gibco, ThermoFisher
Scientifics, Waltham, MA, USA). C2C12 cells were cultured in DMEM
containing 10% FBS. Both culture media were supplemented with 2 mM
glutamine, 100 U/ml penicillin, 0.1 mg/ml streptomycin (EuroClone® S.p.a.,
Pero,MI, Italy), and cells weremaintained at 37°C in a humidified atmosphere
with 5%CO2.Where indicated, in depletionmedia, FBSwas replaced by0.1%
BSA (Sigma-Aldrich, Buchs, SG, Switzerland).
Transfection and generation of the cellular system
For stable transfection, ATDC5cellswere plated in 100-mmdishes at a density
of 2×104/cm2. The next day, cellswere transfectedwith 30 µg of the Pr2.9-Luc
and of theBRE-Lucconstructs, using theLipofectamine 2000 reagent protocol
(Invitrogen, Thermo Fisher Scientifics, Waltham, MA, USA). After 24 h and
for 2weeks, transfected cells weremaintained in completemedium containing
400 µg/ml of Neomycin/G418 (Sigma-Aldrich, Buchs, SG, Switzerland) as
selective agent. Thereafter, Neomycin-resistant clones were picked up and
expanded. For each clone, 1×105 cells were collected after every cell-culture
passage and lysed to evaluate the Luciferase activity with the ONE-Glo™
Luciferase Reporter Assay (Promega Corporation, Madison, WI, USA)
according to the manufacturer’s instruction. Clones showing stable expression
of the reporter gene over the time course were considered suitable for our
purposes and used to set up the culture and treatment protocols in 96-well
format plates.
Screening of the Prestwick Chemical Library in ATDC5 cells
A selected clone of ATDC5 Pr2.9-Luc was seeded into 96-well plates in
depletion medium (3×105 cells/well). After overnight culture, cells were
treated with compounds at the final concentration of 20 μM and 2 μM. We
tested 80 molecules in each plate; cells in columns 1 and 12 were treated
with 1% DMSO as neutral control, resveratrol (10 µM) as positive control
and dipyridamole (20 µM) as negative control (8 wells for DMSO, four
wells for each control).
After 24 h, we measured the effect of the compounds on both cell
viability and Luciferase activity by using the ONE-Glo™+Tox Luciferase
Reporter and Cell Viability Assay (Promega Corporation, Madison, WI,
USA) as suggested by the manufacturer. In brief, 20 µl of the CellTiter-
Fluor Reagent were added in situ to living cells; after 1 h at 37°C, a
fluorescent signal proportional to the number of viable cells in the culture
well was measured by Glomax Multi Detection System (Promega
Corporation, Madison, WI, USA). 100 µl of the second ONE-Glo
Reagent were then added directly to each well to allow cell lysis and
detection of the luciferase signal (GlomaxMulti Detection System, Promega
Corporation, Madison, WI, USA).
Fluorescence (fluo) and luminescence (ACVR1 promoter activity; Lum)
raw data were handled with the Instinct Software (Promega Corporation,
Madison, WI, USA) and analyzed as an Excel spreadsheet. Cell viability
(Vi) was first evaluated by comparing the fluo signal obtained in cells treated
with compounds (fluoCx) versus that of cells exposed to the vehicle [Vi=
(fluoCx/average fluoDMSO)×100, with 0≥Vi≥100]. In parallel, the effect of
compounds (E) on ACVR1 transcriptional activity was evaluated as follows:
first, by normalizing luminescence signal over the fluorescence signal for
each test well (Nx=LumCx/fluoCx) and for the neutral control
(NDMSO=LumDMSO/fluoDMSO), then by comparing the normalized values
of compounds with that of the vehicle [E=(Nx/averageNDMSO)×100].
RNA extraction and quantitative RT-PCR (RT-qPCR)
For expression studies, treated and untreated cells (ATDC5 and C2C12)
were harvested and total RNA was isolated by using the RNeasy Mini Kit
(Qiagen, Valencia, CA, USA), according to the provided protocol.
RNA was quantified with a Nanodrop Spectrophotometer (Thermo
Scientific, Thermo Fisher Scientifics, Waltham, MA, USA), and first-strand
cDNA was synthesized by the Advantage RT-for-PCR Kit (Becton) from
200 ng of total RNA.
Expression of endogenous ACVR1 gene and of selected markers was
evaluated through RT-qPCR using specific TaqMan Gene Expression
Assay (Life Technologies, Thermo Fisher Scientifics, Waltham, MA, USA)
(see Table S3 for specification). Samples were measured in triplicate and
the results were normalized on reference genes 18S, GAPDH and β2-
microglobulin (β2M), depending on the cell line. qPCR was run on the IQ5
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instrument from Bio-Rad and data analysis was performed using the
provided Bio-Rad iQ5 software for Gene Expression Study.
Western blot
For detection of p-Smad, 1.2×106 cells were plated in 100-mm dishes in 1:1
complete/depletion medium for ATDC5 cells, and in depletion medium for
C2C12 (DMEM containing 1% FBS). The next day, serum-starved cells were
treated with Dipy for 24 h and, where indicated, with BMP2 (R&D Systems,
Minneapolis, MN,USA) 200 ng/ml for 1 h. Cells were then washed oncewith
PBSand lysed in 1×RIPAbuffer (50 mMTrisHCl pH7.5, 150 mMNaCl, 1%
Nonidet P-40, 1% sodium deoxycholic, 0.1% SDS) containing phosphatase
and protease inhibitors (PhosSTOP cocktail and Complete tablets, Roche,
Basel, Switzerland). Protein concentration was determined by the Pierce™
BCA Protein Assay Kit (Thermo Scientific, Thermo Fisher Scientifics,
Waltham, MA, USA) according to the manufacturer’s protocol and 15 µg of
total lysates run onto precasted 4-15% Mini Protean®TGX-gels (Bio-Rad,
Hercules, CA, USA). Proteins were transferred onto PVDF membrane
(Millipore, Billerica, MA, USA) and probed with the indicated primary
antibody at 4°C overnight. After incubation with HRP-conjugated secondary
antibodies, protein bands were revealed by chemiluminescence with the ECL
kit (Pierce, Thermo Fisher Scientifics,Waltham,MA,USA) and detectedwith
the ChemiDoc instrument (Bio-Rad, Hercules, CA, USA). Densitometric
analysis of western blot signals was performed by using the ImageJ software.
Culture in 3D pellets
ATDC5 cells were trypsinized from monolayer cultures and 1 ml of cell
suspension with 5×105 cells in DMEM was added to 15 ml polycarbonate
sterile tubes according to Tare et al. (2005). The cell suspension was
centrifuged at 400 g for 10 min at 4°C to obtain pellets that were cultured both
in standard complete medium and in chondrogenic medium containing 10 ng/
ml TGF-β3 (Calbiochem, Millipore, Billerica, MA, USA), 10−8 M
dexamethasone (Sigma-Aldrich, Buchs, SG, Switzerland), 100 mM
ascorbate-2-phosphate (Sigma-Aldrich, Buchs, SG, Switzerland), 1×
insulin-trasferrin-selenium (ITS) solution (Life Technologies, Thermo
Fisher Scientifics, Waltham, MA, USA). Pellets were cultured for 21 days in
a humidified incubator at 37°C and 5% CO2. Pellets were swirled within to
allowmedium access to all sides and prevent adhesion to the inner walls of the
tube. Once compact pellets were formed, both proliferative and differentiating
media were replaced every 3 days and thereafter over the culture period. Three
pellets fromeach groupwere harvested and processed for histological analysis.
Culture in alginate spheres
ATDC5 cells were cultured in alginate spheres according to Culbert et al.
(2014). Briefly, cell suspensions at 6.7×106 cells/ml in 1.2% alginate acid
sodium salt (Sigma-Aldrich, Buchs, SG, Switzerland) solution were
extruded through 16-gauge needles as ∼30 µl drops in 30 ml of 102 mM
CaCl2 (Sigma-Aldrich, Buchs, SG, Switzerland) in order to allow sphere
formation. After drop solidification, cells/alginate spheres werewashed with
PBS and cultured in chondrogenic medium, replenishing every 3 days. A
number of alginate spheres for each condition were formalin-fixed and
processed for histological stainings and immunohistochemical assays. In
parallel, spheres were also incubated with 55 mM sodium citrate (Sigma,
Buchs, SG, Switzerland) to recover cells for total RNA extraction and
expression analysis of markers specific for chondrogenesis such as Runx2,
Sox9, Col II, Col X, aggrecan and also ACVR1 by RT-qPCR with TaqMan
Assays probes (Life Technologies, Thermo Fisher Scientifics, Waltham,
MA, USA) (see Table S3 for specification).
Histological analysis
Cell aggregates were fixed with 4% formaldehyde (Santa Cruz
Biotechnology, Dallas, TX, USA) in PBS for 10-15 min, and
embedded in paraffin according to standard protocols. Paraffin
sections (5 μm) were obtained by microtome, dewaxed and rehydrated
with decreasing ethanol solutions. For histological analysis, sections
were stained with Alcian Blue 8GX (Sigma-Aldrich, Buchs, SG,
Switzerland) following established procedures and viewed in transmitted
and polarized light microscopy.
Immunohistochemistry
Dewaxed and rehydrated sectionswere incubatedwith 3%hydrogen peroxide
in methanol for 30 min to inhibit endogenous peroxidase activity, rinsed in
PBS/0.2% Triton X-100, then were subjected to digestion with 1 mg/ml
hyaluronidase in PBS, pH 6.0 for 15 min at 37°C prior to use. Sections were
exposed to normal goat serum (Dako, Glostrup, Denmark) 1 h before
incubation with the primary antibodies (24 h, 4°C). Slides were then washed
with PBS (four times for 5 min each) and incubatedwith theHRP-conjugated
secondary antibodies for 1 h at room temperature (RT). The peroxidase
reaction was developed using 3,3′-diaminobenzidine tetrahydrochloride
(DAB) as chromogens. After rinsing in distilled water, sections were
dehydrated in increasing ethanol solutions, cleared in xylene and mounted.
C2C12 cell culture and osteogenic differentiation
In order to induce C2C12 differentiation towards the osteoblastic lineage
(Katagiri et al., 1994), 1.2×104 cells were seeded in 6-well plates and
cultured in complete medium supplemented with 5% FBS (low-mitogen
medium). The day after, cells were treated with 300 ng/ml BMP2 (R&D
Systems, Minneapolis, MN, USA) for 6 days. Where indicated, Dipy
(50 µM) was also added to both standard and differentiating media.
Cells were processed to evaluate the alkaline phosphatase (ALP)
enzymatic activity by the Alkaline Phosphatase (Sigma Diagnostics,
Buchs, SG, Switzerland) kit following the manufacturer’s instructions and
total RNA was extracted to evaluate the expression of Runx2, osterix and
osteocalcin by RT-qPCR with TaqMan Assays probes. In order to quantify
the ALP activity in C2C12 cells induced by BMP2 treatment, 5×103 cells
were plated in CellCarrier-96-well™ microplates (Perkin Elmer, Waltham,
MA, USA) and cultured in the presence of BMP2±Dipy as described. After
6 days, Hoechst 33342 Nuclear Stain (ENZ-51031-HOE33342, Enzo Life
Sciences) was added to the culture medium at a 1:1000 dilution and
incubated for 20 min. Cells were then visualized with the NIKON Ti Eclipse
microscope; 16 640×490-µm fields for each well and condition were
acquired and analyzed by the NIS-Elements AR software to obtain an
automated count of the present nuclei. The number of nuclei has been used
to normalize the ALP activity measured as follows. After analysis, cells were
washed with PBS and incubated with 200 μl of the Alkaline Phosphatase
Yellow liquid substrate system (nNPP) (Sigma, Buchs, SG, Switzerland).
Reaction was stopped with 60 μl 3 M NaOH and ALP activity measured at
405 nm by Mithras LB940 plate reader (Berthold Technologies).
Heterotopic ossification in vivo
0.05 μg/μl of BMP2 (Peprotech, Rocky Hill, NJ, USA) in 200 μl growth-
factor-reduced Matrigel (BD Biosciences) were injected intramuscularly in
the quadriceps of C57BL/6 2-month-old mice (11 mice/group). The
contralateral muscle was used as internal control and injected with Matrigel
only. Both quadriceps were injected with 50 μl cardiotoxin 5 μM (CTX
from Naja mossambica mossambica, Sigma-Aldrich, Buchs, SG,
Switzerland) to increase muscle damage. Animals were anesthetized by
inhalation of 2-bromo-2-chloro-1,1,1-trifluoroethane, ≥99% (CAS no. 151-
67-7, Sigma-Aldrich, Buchs, SG, Switzerland) before the injection. 10 mg/
kg (body weight) dipyridamole was administered daily IP to the treated
animals (n=11, for Protocol A; n=5 for Protocol B, see Fig. S5) in a solution
composed of 10% ethanol, 5% 2-pyrolidone, 12-15% propylene glycol,
10% Cremophor ELP, saline to 100% (Wang et al., 2013). Control mice
(n=11, for Protocol A; n=5 for Protocol B, see Fig. S5) received the injection
solution without drug. Mice were housed at the San Raffaele Institute SPF
animal facility and were kept in pathogen-free conditions. All procedures
were in accordance with Italian law and were performed under internal
regulations for animal care and handling.
In vivo CT imaging of heterotopic ossification
At day 10 and 21 after BMP injection, in vivo micro-computerized
tomography (μCT) scans were carried out to assess progression of
ossification and any effect on the normal skeletal structure. In vivo µCT
imaging was performed using the IVIS SpectrumCT Pre-clinical in vivo
imaging system (Perkin-Elmer, Waltham, MA, USA). CT images were
acquired without any contrast medium with the following parameters: x-ray
694


















tube voltage=50 kV, tube current=1 mA, x-ray focal spot size=50 μm. The
CT images calibrated in Hounsfield unit (HU) were reconstructed with a
voxel size of 75 μm3. Threshold-based image segmentation were performed
to obtain a 3D reconstruction and quantification of the ossification.
The totalmineralized volumeV=N×voxel size (mm3)was quantified using
MIPAV (medical imaging processing analysis and visualization) and
MATLAB software, where N is the number of voxels corresponding to
bone derived from the image segmentation procedure. The bone density
quantificationwas calculated by using the following formula:∑Ni=1HUi/V.
Morphological and histochemical analysis of the heterotopic
ossification
At 21 days after BMP injection, muscles were collected and processed for
further morphological and histological analyses. BMP/Matrigel-injected
and Matrigel-injected quadriceps from treated and control mice were frozen
in liquid-nitrogen-cooled isopentane, to allow preparation of 10-μm-thick
sections.
Muscle sections were stained with hematoxylin and eosin (H&E) (Sigma-
Aldrich, Buchs, SG, Switzerland) or Toluidine Blue (Bio-Optica, Milano,
Italy) or Alizarin Red (Sigma-Aldrich, Buchs, SG, Switzerland) according
to the manufacturers’ instructions. Images were acquired using a Nikon
Eclipse E600 microscope (Nikon, Tokyo, Japan). To quantify heterotopic
ossification, images of Alizarin-Red-stained sections were subsequently
analyzed using the batch mode of the ImageJ vs1.49 macro. The color
thresholding algorithm used by this macro is based on an algorithm written
by G. Landini (version v1.8) available at http://www.mecourse.com/
landinig/software/software.html.
Immunofluorescence on muscle sections
For immunofluorescence, 8-μm sections from OCT-embedded muscles
were fixed with 4% PFA in PBS. They were permeabilized with a 0.2%
Triton X-100, 1% BSA solution in PBS for 30 min at RT and then blocked
in 10% serum, 1% BSA solution in PBS for 30 min before incubation with
the primary antibody p-Smad1/5 (1:800; Cell Signaling, Danvers, MA,
USA), after a demasking step in sodium citrate 10 mM pH 6 for 10 min
between fixation and blocking steps (2 h). Alexa-Fluor-546-conjugated
antibody (1:500; Invitrogen, Thermo Fisher Scientifics, Waltham, MA,
USA) was used as second-step reagents. Specimens were counterstained
with DAPI (Sigma, Buchs, SG, Switzerland) and analyzed using a Zeiss
LSM710 confocal microscope. Images showing double fluorescence were
first acquired separately using appropriate filters, then the different layers
were merged using Adobe Photoshop CS4.
Statistical analysis
All luciferase reporter gene assays were performed in triplicate and repeated
independently at least twice (2-5 times). Z′ factor was evaluated by using the
formula [Z′=1−3×(σs+σc)/|µs−µc|], where σs and σc are the s.d. of positive or
negative sample and of the solvent (control) and µs and µc represent the
average. Experiments to evaluate gene expression by RT-qPCR were
performed in triplicate from at least two independent RNA extractions. Both
the non-parametric Mann–Whitney test (Social Science Statistics) and the
unpaired two-tailed Student’s t-test (GraphPad t-test Calculator; http://
graphpad.com/quickcalcs/ttest1.cfm) were applied to verify statistical
significance of the observed variations. Significant differences were given
as *P<0.05, #P<0.01 or §P<0.001.
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Figure S1. Resveratrol is able to up-regulate ACVR1 expression at transcriptional level. 
ATDC5 cells were treated with 20 µM resveratrol for 24 hours. (A) Effect of resveratrol on the 
Luciferase reporter gene controlled by the promoter region of ACVR1 in ATDC5 cells (Pr2.9-Luc). 
The ratio of Luciferase/fluorescence was normalized to that obtained with DMSO (value 100). Bar 
graphs represent the mean and SD of three independent experiments, 
§
p < 0.001. (B) Effect of 
resveratrol on the expression of ACVR1 mRNA in native ATDC5 cells. Values were normalized on 
GAPDH and ß2M and compared to expression level measured in cells treated with DMSO. Bar 
graphs represent the mean and SD of at least three experiments, 
§
p < 0.001.  
 

































Figure S2. High through-put screening for compounds able to target expression of the ACVR1 gene 
at the promoter level. (A) Schematic representation of the whole procedure. (B) Results of the 
Prestwick Chemical library primary screening. Black diamonds are the mean of the effect of a single 
compound on Luciferase reporter gene controlled by the promoter region of ACVR1 in ATDC5 
Pr2.9-Luc cells. Luciferase activity was normalized on a fluorescence signal proportional to viable 
cells. The ratio of Luc/fluo*100 was compared to that obtained with the DMSO (value 100). Red 
diamond and arrow indicate Dipy. 
 

































Figure S3. Effect of Dipy on mRNA expression of type I and type II BMP receptors.  
RT-qPCR analysis in native ATDC5 cells treated with the indicated doses of Dipy. Expression 
levels were normalized on ß2M reference gene (relative quantification by the ∆Ct method: ratio 
reference/target=2
∆Ct




































Figure S4. Effect of Dipy on osteoblastic differentiation of C2C12 cells.  
Hoechst staining of C2C12 cells differentiated towards the osteoblastic lineage upon BMP2 
induction for 6 days and treated with Dipy at the indicated concentrations. A representative field for 
each condition is shown. Scale bar 50 µm. 


































Figure S5. Effect of Dipy on ectopic ossification in a BMP-induced mouse model. We applied two 
different treatment strategies, preventive versus effect on an already formed ectopic ossicle. In the 
first case, Dipy was chronically administered to mice starting from the same day of heterotopic 
ossification induction and for 21 days. In the second protocol, we did induce the ectopic ossicles 
formation for ten days, then we started to treat mice with Dipy until day 21. MicroCT scans were 
performed at 10 days on living animals and then at 21 days, before sacrifice for histological and 
immuno-histochemical analyses. 
 


































Figure S6. Histological analysis of HO lesions in vivo Toluidine Blue staining showing deposition 
of extracellular glycosaminoglycans of the matrix in control and Dipy-treated mice after 10 and 21 
days of treatment. Scale Bar: 100 µm. 
 
 






























Figure S7. In vivo effect of Dipy on the Smad1/5/8-mediated BMP pathway.  
(A)Representative confocal images of HO lesions in cross-sections quadriceps muscle 
immunostained for Phospho-Smad1/5 ( (P-SMAD1/5) (red), from control and Dipy treated-mice, 
10- and 21 days after BMP induced HO and Dipy/vehicle treatment. Nuclei are stained with DAPI 
(blue). Magnification 40X and 80X, Scale bar: 20 µM. (B) Quantification of P-SMAD1/5
+
 cells
measured as the number of positive cells among the total cells per square millimeter in the HO 
lesions of quadriceps muscles immunostained for P-SMAD1/5 from control (black histograms,) and 
Dipy treated-mice (grey histograms), 10- and 21 days after BMP induced HO and Dipy/vehicle 






























treatment. Data are expressed as means ± SD, with n=3 for both control and Dipy treated mice at 10 




Figure S8. Effect of Dipy on already established HO lesions in vivo. (A) Micro Computerized 
Tomography (µCT) scans of C57Bl/6 mice 10 and 21 days after BMP2-CTX induced HO (n=10). 
At 10 days after BMP2 injection, mice were either treated with the Vehicle (n=5) or Dipy (n=5) 
(10mg/kg) for additional 11 days.(B) Quantification of the Ossicles mineralized volume. Data 
represent mean ± SEM (at 21 days p=0.2). (C) Box-plot showing the variance (∆21d-10d) of the 
mineralized volume between day 21 and 10, for each mice. Data represents mean ± SEM (p=0.078). 
 
































Figure S9. Histological analysis of the effect of Dipy on already established HO lesion in vivo. (A) 
Haematoxylin and eosin (H&E) staining of ectopic lesions in muscle of mice treated with the 
Vehicle or Dipy starting from day 10 after BMP-CTX injection. Scale bar: 1mm. Alizarin Red S 
staining showing calcium deposit in tissue sections of in mice treated with the Vehicle or Dipy 
starting from day 10 after BMP2-CTX injection. Scale Bar: H&E (upper panels) 1 mm; Alizarin 
Red (lower panels) 500 µm. (B) Graph representing the relative quantification of the Alizarin Red S 
positive area. Data represent mean ± SEM, *p≤ 0.05 (n=3, Dipy vs control). 
 
 



































*Luciferase activity was normalized on a fluorescence signal proportional to viable cells. The ratio of Luc/fluo*100 was 
compared to that obtained with the DMSO (value 100). 
 
Compound Normalized Luc/Fluo* Pharmacological class 
  20 µM 2 µM   
Danazol 0,569 ± 0,009 0,610 ± 0,052 Synthetic Steroid 
Dexametasone acetate 0,667 ± 0,072 0,557 ± 0,054 Antinflammatory 
Halcinonide 0,552 ± 0,025 0,702 ± 0,086 Topic Corticosteriod 
Medrysone 0,551 ± 0,034 0,685 ± 0,065 Topic Corticosteriod 
Fluocinonide 0,595 ± 0,124 0,577 ± 0,039 Topic Corticosteriod 
Clobetasol propionate 0,589 ± 0,005 0,673 ± 0,037 Topic Corticosteriod 
Cortisol acetate 0,590 ± 0,081 0,642 ± 0,046 Steroid Hormone 
Fluticasone propinate 0,689 ± 0,004 0,538 ± 0,035 Corticosteriod 
Dipyridamole 0,421 ± 0,025 0,624 ± 0,049 Platelet Antiagregant 
Haloperidol 0,597 ± 0,054 0,655 ± 0,015 Antipsychotic 
Naloxone HCl 0,788 ± 0,009 0,597 ± 0,143 Opiate Antidote 
Glizpide 0,759 ± 0,038 0,594 ± 0,109 Hypoglycemic 
Chloroxine 0,524 ± 0,055 1,178 ± 0,027 Antiseborrheic 
Acitretin 0,841 ± 0,012 0,574 ± 0,096 Antipsoriatic 
Ioxaglic acid 0,798 ± 0,013 0,590 ± 0,011 Contrastant 
Bethanecol chloride 0,723 ± 0,005 0,596 ± 0,029 Myotonic 
Prednisolone 0,784 ± 0,251 0,637 ± 0,068 Antinflammatory 
Naproxen 0,757 ± 0,044 0,768 ± 0,101 FANS 
Nabumetone 2,401 ± 0,869 1,698 ± 0,138 Analgesic/FANS 
Methiazole 2,905 ± 0,052 1,944 ±0,405 Antiparasitic 
Nocodazole 2,425 ± 0,337 1,271 ±0,148 Antineoplastic 
Nalmefene hydrochloride 2,944 ± 2,370 0,990 ± 0,337 Narcotic Antagonist 































Table S2. Densitometric analysis corresponding to the anti P-Smad1/5 western blot analysis 
shown in Figure 2 (panels C and D) 
 
 
 ATDC5 cells C2C12 cells 
Dipy - - 20 µM 50 µM - - 20 µM 50 µM 
BMP2 - + + + - - + + 










Numbers indicate the fold activation as a result of the densitometric analysis performed by the ImageJ software. 
Intensity of immunobands obtained with the specific anti P-Smad1/5 antibodies were normalized against intensity of 
bands obtained with anti-GAPDH antibodies and compared to untreated cells (value 1). 
a,b,c,d
 Two tail unpaired t-test analysis: BMP2-activated versus BMP2/Dipy treated cells. 










































































Murine Genes Taq Man assay 
ACVR1/ALK2  Mn00431645_m1 
GAPDH  Mn99999915_g1 
ß 2 Microglobulin Mn00437762_m1 
RN18s Mm03928990_g1 
Sox 9 Mm00448840_m1 
Runx2 Mm005001584_m1 
Col II Mm01309565_m1 
Col X Mm00487041_m1 
ALPl Mm00475834_m1 
Osterix Mm00504574_m1 
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